Eloxx Pharmaceuticals, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sumit Aggarwal
- Full Time Employees
- 18
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 480 Arsenal Way Watertown MA United States of America 02472
- IPO Date
- Apr 26, 1999
- CIK
- 0001035354
- Website
- eloxxpharma.com
- Similar Companies
- Business
- Eloxx Pharmaceuticals, Inc. (ELOX) is a clinical-stage biopharmaceutical company focused on developing ribosome modulation therapies for rare and ultra-rare premature stop codon diseases caused by nonsense mutations. The company offers ELX-02, its lead investigational small molecule candidate in Phase 2 clinical trials for cystic fibrosis and nephropathic cystinosis patients with nonsense mutations; preclinical programs targeting Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis; and earlier discovery-stage initiatives in oncology. Founded in 2013 and headquartered at 480 Arsenal Way, Suite 130, Watertown, Massachusetts, Eloxx operates primarily in the United States with a pipeline addressing genetic diseases including those involving collagen IV, COL7A1, and Kir7.1 mechanisms. Recent developments include securing $3.2 million in additional bridge financing through amendments to its 2021 Loan and Security Agreement with Hercules Capital and others in July 2024, comprising a Tranche 2 Advance and prior May funding to support clinical programs; entering a Royalty and Revenue Sharing Agreement with Domicilium Fund III LP capping payments at $53 million tied to ELX-02 milestones and net sales; and advancing pipeline efforts highlighted in its July 2024 investor presentation featuring two clinical-stage small molecule therapies with global partnership support.
Contrasting Eloxx Pharmaceuticals (NASDAQ:ELOX) & Prime Medicine (NYSE:PRME)
Critical Contrast: Eloxx Pharmaceuticals (NASDAQ:ELOX) & Finch Therapeutics Group (NASDAQ:FNCH)
Contrasting Finch Therapeutics Group (NASDAQ:FNCH) and Eloxx Pharmaceuticals (NASDAQ:ELOX)
Critical Contrast: Cortexyme (NASDAQ:CRTX) vs. Eloxx Pharmaceuticals (NASDAQ:ELOX)
Cortexyme (NASDAQ:CRTX) versus Eloxx Pharmaceuticals (NASDAQ:ELOX) Critical Contrast
Cortexyme (NASDAQ:CRTX) & Eloxx Pharmaceuticals (NASDAQ:ELOX) Head to Head Survey
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
This Small Cap Stock Surged Over 100%